Zacks.com on MSN2h
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
labiotech6h
mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics
In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.
STAT7h
Tris Pharma, looking to compete with Vertex, reports acute pain trial success
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...